104 related articles for article (PubMed ID: 9110338)
1. The taxanes: dosing and scheduling considerations.
Rowinsky EK
Oncology (Williston Park); 1997 Mar; 11(3 Suppl 2):7-19. PubMed ID: 9110338
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel: a review of its pharmacology and clinical activity.
Trudeau ME
Can J Oncol; 1996 Jun; 6(1):443-57. PubMed ID: 8853517
[TBL] [Abstract][Full Text] [Related]
3. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
Hainsworth JD; Raefsky EL; Greco FA
Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489
[TBL] [Abstract][Full Text] [Related]
5. Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Radaideh SM; Sledge GW
Breast Cancer Res Treat; 2008 Sep; 111(2):203-8. PubMed ID: 17990102
[TBL] [Abstract][Full Text] [Related]
6. Dose-intense paclitaxel: deja vu all over again?
Takimoto CH; Rowinsky EK
J Clin Oncol; 2003 Aug; 21(15):2810-4. PubMed ID: 12807932
[No Abstract] [Full Text] [Related]
7. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
8. Is there a place for "dose-dense" weekly schedules of the taxoids?
Löffler TM
Semin Oncol; 1998 Oct; 25(5 Suppl 12):32-4. PubMed ID: 9865710
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
[TBL] [Abstract][Full Text] [Related]
10. Weekly administration of docetaxel (Taxotere): summary of clinical data.
Hainsworth JD; Burris HA; Greco FA
Semin Oncol; 1999 Jun; 26(3 Suppl 10):19-24. PubMed ID: 10437747
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Hainsworth JD; Greco FA
Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel dose intensity.
Reed E; Bitton R; Sarosy G; Kohn E
J Infus Chemother; 1996; 6(2):59-63. PubMed ID: 8809650
[TBL] [Abstract][Full Text] [Related]
13. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
14. A simplified premedication schedule for 1-hour paclitaxel administration.
Tsavaris N; Kosmas C; Vadiaka M
J Support Oncol; 2005; 3(1):77-81. PubMed ID: 15724950
[TBL] [Abstract][Full Text] [Related]
15. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
16. Weekly schedules of docetaxel.
Burris H
Semin Oncol; 1998 Dec; 25(6 Suppl 13):21-3. PubMed ID: 9865688
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
Hájek R; Vorlicek J; Slavik M
Neoplasma; 1996; 43(3):141-54. PubMed ID: 8841500
[TBL] [Abstract][Full Text] [Related]
18. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel: current developmental approaches of the National Cancer Institute.
Arbuck SG
Semin Oncol; 1995 Dec; 22(6 Suppl 15):55-63. PubMed ID: 8643972
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
